In this #AMPtutorials, we will discuss the role of the TMPRSS2::ERG fusion in prostate cancer (PCa), and its therapeutic implications. What do you know about the fusion? 🧬 #Molpath #GUpath #ProstateCancer @AMPath @MGBpathology @MGHPathology

How do ERG and the androgen receptor interplay in prostate cancer? #AMPtutorials #Molpath #GUpath #ProstateCancer

What are the physiological functions of the ERG transcription factor, and how does ERG overexpression contribute to the development and progression of prostate cancer? #AMPtutorials #Molpath #GUpath #ProstateCancer

Which signaling pathways are associated with ERG overexpression in prostate cancer? #AMPtutorials #Molpath #GUpath #ProstateCancer

Why detecting TMPRSS2::ERG fusion is important, and how to test for it? #AMPtutorials #Molpath #GUpath #ProstateCancer

What are the potential therapeutic targets for prostate cancer with TMPRSS2::ERG fusion? #AMPtutorials #Molpath #GUpath #ProstateCancer

@AMPath @MGBpathology @MGHPathology Many thanks to Dr. Dias-Santagata for the mentorship! Disclosure: This educational resource does not constitute medical or legal advice and is not intended for use in the diagnosis or treatment of individual conditions. #AMPtutorials

@TingZhaoPathdoc @AMPath @MGBpathology @MGHPathology Great tutorial. Would use it with caution if the upregulated fusion gene is a lineage marker as well. Brigham abandoned FLI1 IHC as a vascular marker a few years ago because some ordering pathologists used it as a surrogate for EWSR1::FLI1 and ended up with misdiagnosis.